The human papillomavirus (HPV) vaccine has effectively eliminated cervical cancer deaths among women aged 20 to 24 in England, according to a study published in The Lancet. Researchers from Queen Mary University of London found that between 2020 and 2024, there were zero recorded deaths from the disease in this age cohort. This milestone represents a significant public health achievement, with the vaccine estimated to have prevented nearly 200 deaths in young women since its introduction.
How effective is the HPV vaccine in preventing cervical cancer?
Data from the Queen Mary University of London study indicates that the vaccine provides near-total protection when administered at the recommended age. Children vaccinated at age 12 or 13, when the inoculation is most effective, now face almost zero risk of dying from cervical cancer before age 30. This research, funded by Cancer Research UK, marks the first time scientists have directly linked national vaccination programs to a complete absence of cervical cancer mortality in a specific age group.
Australia was the global pioneer in this field, becoming the first country to launch a publicly funded, school-based HPV vaccination program for adolescent girls in 2007.
Why is the current vaccination uptake a concern?
Despite the high efficacy of the vaccine, health officials warn that progress is at risk due to declining participation rates. Michelle Mitchell, chief executive of Cancer Research UK, noted that vaccination coverage in the UK currently falls short of the 90 percent target recommended by the World Health Organization (WHO). Recent figures show that between 76 and 86 percent of girls are vaccinated by age 15, leaving a gap that could lead to preventable cases in the future.
How does this compare to international efforts?
The UK’s success mirrors global ambitions to eradicate the virus. In 2020, the WHO launched a comprehensive global strategy aimed at the total elimination of cervical cancer. While the UK rolled out the vaccine for girls in 2008 and expanded the program to include boys in 2019, other nations are at different stages of implementation. Researchers suggest that as these vaccinated generations age, the reduction in mortality will likely extend far beyond the 30-year-old threshold.
Vaccination is most effective when administered during early adolescence. Health systems emphasize that maintaining high coverage rates is essential to preventing the resurgence of HPV-related cancers.
Frequently Asked Questions
- What is HPV? HPV is the most common sexually transmitted infection. Certain high-risk strains are known to cause cervical, vulvar, vaginal, and other cancers.
- When should the HPV vaccine be given? The vaccine is most effective when administered to children aged 12–13, before potential exposure to the virus.
- Is the vaccine available for boys? Yes, in the UK, the vaccination program was expanded to include boys in 2019 to help reduce the transmission of the virus.
- Does the vaccine replace cervical screening? No. Health organizations continue to recommend regular cervical screening alongside vaccination to ensure comprehensive protection.
Have questions about the HPV vaccine or local health guidelines? Check your national health service website for the latest information on vaccination schedules. If you found this update helpful, subscribe to our health newsletter for the latest medical research and public health news.